Banner placeholder


This page is for Healthcare Professionals only

Managed Access Programme

Access to Dinutuximab beta

In collaboration with Idis, EUSA Pharma will continue the Managed Access Program set up by Apeiron Biologics in order to satisfy requests from physicians for access to dinutuximab beta for patients with high-risk neuroblastoma. The Managed Access Program will provide access to dinutuximab beta in certain, defined countries in line with local country specific regulations. EUSA Pharma can only provide access in response to unsolicited requests from qualified physicians for an individual patient with no alternative treatment options.

If you are a qualified healthcare professional, please contact an Idis representative on the contact details given below to learn more about the availability of dinutuximab beta in your country.

neuroblastoma@idispharma.com
Tel: + 44 (0)1932 824123
Fax: + 44 (0)1932 824323

Idis cannot respond to direct enquiries from patients, parents or carers. If you are a relative of a patient, looking for information regarding the availability of dinutuximab beta in your country, then please discuss this with your physician, or refer your physician directly to Idis.

EUSA Pharma
Ground Floor, Suite F
Breakspear Park
Breakspear Way
Hemel Hempstead
HP2 4TZ

NP/GLB/NPS/2016/01.01
Date of prep: Oct 2016